Overcoming the Causes (and Consequences) of Chronic Hyperkalemia
Annenberg Center for Health Sciences
5 episodes
19 hours ago
Chronic hyperkalemia has several possible causes, including impaired renal excretion of potassium due to a decrease in mineralocorticoid activity, often resulting from renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. While limiting potassium intake and avoiding the use of RAASi therapy are common strategies to manage patients who develop chronic hyperkalemia, both have important negative consequences on patient outcomes, particularly related to the kidneys. Sodium polystyrene sulfonate has often been used to bind potassium, but limited effectiveness and gastrointestinal toxicity
All content for Overcoming the Causes (and Consequences) of Chronic Hyperkalemia is the property of Annenberg Center for Health Sciences and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Chronic hyperkalemia has several possible causes, including impaired renal excretion of potassium due to a decrease in mineralocorticoid activity, often resulting from renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. While limiting potassium intake and avoiding the use of RAASi therapy are common strategies to manage patients who develop chronic hyperkalemia, both have important negative consequences on patient outcomes, particularly related to the kidneys. Sodium polystyrene sulfonate has often been used to bind potassium, but limited effectiveness and gastrointestinal toxicity
Overcoming the Causes (and Consequences) of Chronic Hyperkalemia
10 minutes 36 seconds
3 years ago
Potassium-binding Medications
Safety & efficacy of patiromer
Safety & efficacy of sodium zirconium cyclosilicate
Overcoming the Causes (and Consequences) of Chronic Hyperkalemia
Chronic hyperkalemia has several possible causes, including impaired renal excretion of potassium due to a decrease in mineralocorticoid activity, often resulting from renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. While limiting potassium intake and avoiding the use of RAASi therapy are common strategies to manage patients who develop chronic hyperkalemia, both have important negative consequences on patient outcomes, particularly related to the kidneys. Sodium polystyrene sulfonate has often been used to bind potassium, but limited effectiveness and gastrointestinal toxicity
